OBX-115

N/A

Report date: 2026/04/17 10:36:35

Base Information

Drug NameOBX-115

Drug Alias NameIL15-CA2 DRD modified T cells (Obsidian Therapeutics)OBX115cytoTIL15cytoTIL15-LIGHT

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tumor Infiltrating Lymphocytes

Mechanisms of ActionLymphocyte replacementsInterleukin-15 receptors agonists

TargetsInterleukin-15 receptors

Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungLung NeoplasmsSkin Neoplasms +[5]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesObsidian Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Texas MD Anderson Cancer Center Obsidian Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsCarcinoma, Non-Small-Cell LungLung NeoplasmsSkin Neoplasms +[4]

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A